Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04787341
Title PAnitumumab REchallenge Followed by REgorafenib Versus the Reverse Sequence (PARERE)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Gruppo Oncologico del Nord-Ovest
Indications

colorectal cancer

Therapies

Regorafenib

Panitumumab

Age Groups: adult | senior
Covered Countries ITA

Additional content available in CKB BOOST